Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc.Jan 28 2010

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

“IMO-3100 is our fourth compound to advance into clinical development, each for a different therapeutic application.”

“As an antagonist of TLR7 and TLR9, IMO-3100 has a novel mechanism of action and presents a potentially innovative approach in the treatment of a number of autoimmune diseases,” said Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer. “IMO-3100 is our fourth compound to advance into clinical development, each for a different therapeutic application.”

“Our first step in the clinical evaluation of IMO-3100 is to assess the safety and mechanism of action in healthy subjects,” said Tim Sullivan, Ph.D., Vice President of Development Programs. “We have observed exciting results that show IMO-3100 ameliorates the pathologic findings observed in preclinical models of various autoimmune diseases, including lupus, rheumatoid arthritis, and psoriasis. Data from this Phase 1 clinical trial will support our decisions regarding subsequent clinical development of IMO-3100.”